BiPar Sciences Presents Interim Phase 2 Results for PARP Inhibitor BSI-201 At San Antonio Breast Cancer Symposium
December 12, 2008 08:05 ET
|
BiPar Sciences
BRISBANE, Calif., Dec. 12, 2008 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing poly (ADP-ribose) polymerase (PARP) inhibitors as novel cancer...
BiPar Sciences Receives 2008 Emerging Technology Award in Biotechnology
December 10, 2008 09:30 ET
|
BiPar Sciences
BRISBANE, Calif., Dec. 10, 2008 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, has received the 2008...
BiPar Sciences to Present At the 31st CTRC-AACR Annual San Antonio Breast Cancer Symposium
December 04, 2008 09:30 ET
|
BiPar Sciences
BRISBANE, Calif., Dec. 4, 2008 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, announced today that the...
BiPar Sciences' Lead Compound Selected as Top 10 Oncology Drug Candidate
October 28, 2008 09:00 ET
|
BiPar Sciences
BRISBANE, Calif., Oct. 28, 2008 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, today announced that its lead...
BiPar to Present at the 7th Annual BIO Investor Forum in San Francisco
October 21, 2008 10:00 ET
|
BiPar Sciences
BRISBANE, Calif., Oct. 21, 2008 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, announced today that John...
BiPar Sciences Announces Senior Appointments in Corporate Development and Legal Functions
September 23, 2008 09:00 ET
|
BiPar Sciences
BRISBANE, Calif., Sept. 23, 2008 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, today announced that it has...